Navigation Links
Sunridge to Introduce Their PNT Treatment for Glaucoma to Medical Personnel in India
Date:9/28/2010

FOUNTAIN HILLS, Ariz., Sept. 28 /PRNewswire/ -- Sunridge International (OTC Bulletin Board: SNDZ) said today that their treatment for glaucoma and ocular hypertension will be introduced in October to eye doctors and the medical community in India.

Presentations have been planned by its Indian distributors, New Amsterdam Marketing Corporation, in major cities from October 1 – 14.  The company's Pneumatic Trabeculoplasty (PNT), treatment is a cost-effective, non-invasive procedure designed to reduce pressure on the retinal nerve. The two-minute procedure, easily performed in a clinic or doctors office, is required only three or four times a year. It is a treatment regime that is especially valuable to patients in rural areas, where traditional medical facilities are limited.

Sunridge International, the developer and marketer of the PNT treatment, announced today that it's exclusive marketer in India, will be holding meetings to demonstrate the procedure to hundreds of medical personnel throughout the country.

The first presentations will be held at the (www.apos.in) conference in Hyderabad from October 1-3. This will be followed by meetings in Calcutta, Mumbai and Jaipur. The presentations will be led by Dr. Leo Bores, M.D.  Dr. Bores also will be holding private meetings over a two week period in India.

G. Richard Smith, CEO of Sunridge International, said the company was especially pleased to be able to bring the PNT procedure to India. "We are introducing our PNT equipment and treatments in many markets throughout the world, including the European Union countries, China and Latin America. But India is a very special place. It offers enormous opportunity for us."

"Working with New Amsterdam colleagues, we look forward to helping, perhaps, thousands of people suffering from glaucoma and ocular hypertension throughout the country. Often in the rural countryside, with a very poor population, glaucoma is left untreated. For many the cost of ongoing treatment is simply out of their reach. We strongly believe that PNT provides an answer to this problem, and gives people an opportunity for a safe, effective and affordable treatment.

"We will be giving the doctors and medical personnel attending the New Amsterdam presentations our fullest support and look forward to a long and mutually rewarding association with them."

Glaucoma is the second leading cause of blindness, affecting more than 70 million people worldwide. Studies completed over the last 10 years have proven that PNT is a safe effective and cost effective alternative treatment for glaucoma and ocular hypertension. The two-minute treatment has been developed, patented and distributed by Sunridge International's wholly-owned subsidiary, Ophthalmic International.(www.oi-pnt.com).CONTACT:Jeff Smith, Sunridge International   T:  +1-480-837-6165e-mail: info@sunridgeint.com website: www.sunridgeint.com MEDIA:Victor Webb, Marston Webb InternationalT: (212) 684-6601e-mail: marwebint@cs.com
'/>"/>

SOURCE Sunridge International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunridge Announces Marketing Roll Out of PNT in the Dominican Republic
2. Sunridge Schedules European Meetings
3. Sunridge Ships First Order to the Middle East
4. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
5. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
6. Dr. Dello Russo Introduces the New EYE-Q Lasik
7. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
8. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
9. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
10. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
(Date:11/30/2016)... 2016 Research and Markets has announced the ... MedCore" report to their offering. ... , Detachable coil embolization is ... malformations. The detachable coil embolization treatment of cerebral aneurysms is less invasive ... weakened area in the wall of an artery in the brain. This ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) ... by autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being ... and other caregivers the opportunity to share stories and advice, seek help, and continue ...
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical ... systems and the first company to offer robotic imaging to veterinary medicine is ... booth # 941 for the American Association of Equine Practitioners 62nd Annual Convention ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:11/30/2016)... Massachusetts (PRWEB) , ... November 30, 2016 , ... ... proud to announce that we have been designated as a Cigna Infertility Center ... or exceed rigorous performance standards. , “It’s an honor to be designated ...
Breaking Medicine News(10 mins):